Aldeyra Therapeutics Inc
NASDAQ:ALDX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Aldeyra Therapeutics Inc
NASDAQ:ALDX
|
US |
|
Block Inc
OTC:BSQKZ
|
US |
|
C
|
Coretronic Corp
TPEX:5371
|
TW |
|
D
|
Dynagreen Environmental Protection Group Co Ltd
F:DYN
|
CN |
|
Block Inc
ASX:XYZ
|
US |
|
A
|
AMETEK Inc
XMUN:AK1
|
US |
|
Cuscal Ltd
F:Y49
|
AU |
|
B
|
Ballard Power Systems Inc
XBER:PO0
|
CA |
|
B
|
Ballard Power Systems Inc
SWB:PO0
|
CA |
|
CIELO SA Instituicao de Pagamento
F:28MA
|
BR |
Aldeyra Therapeutics Inc
Aldeyra Therapeutics is a biotechnology company that develops prescription medicines for eye and immune-related diseases. Its lead work has focused on inflammatory conditions of the eye, along with other diseases driven by abnormal inflammation and immune activity. The company is not a drug retailer or hospital chain; it is a drug developer that works upstream in the healthcare value chain, turning research into potential treatments. The company’s main business is to discover, test, and seek approval for its own drug candidates, then license or commercialize them if they reach the market. In this model, it makes money only if a medicine is approved and sold, either directly or through a partner. Its customers would be doctors, patients, and health systems that use the approved therapies, with insurers and pharmacy benefit managers often affecting access and reimbursement. What makes Aldeyra different is that it is built around a small number of targeted drug programs rather than a broad portfolio of approved products. That means its business depends heavily on scientific and regulatory success, but it also gives the company a focused role: trying to create treatments for diseases where current options may not fully address inflammation or immune dysfunction.
Aldeyra Therapeutics is a biotechnology company that develops prescription medicines for eye and immune-related diseases. Its lead work has focused on inflammatory conditions of the eye, along with other diseases driven by abnormal inflammation and immune activity. The company is not a drug retailer or hospital chain; it is a drug developer that works upstream in the healthcare value chain, turning research into potential treatments.
The company’s main business is to discover, test, and seek approval for its own drug candidates, then license or commercialize them if they reach the market. In this model, it makes money only if a medicine is approved and sold, either directly or through a partner. Its customers would be doctors, patients, and health systems that use the approved therapies, with insurers and pharmacy benefit managers often affecting access and reimbursement.
What makes Aldeyra different is that it is built around a small number of targeted drug programs rather than a broad portfolio of approved products. That means its business depends heavily on scientific and regulatory success, but it also gives the company a focused role: trying to create treatments for diseases where current options may not fully address inflammation or immune dysfunction.
Clinical Progress: Aldeyra achieved FDA acceptance of two new drug applications—Reproxalap for dry eye disease and ADX-2191 for primary vitreoretinal lymphoma, the latter receiving priority review.
Pipeline Expansion: The company is advancing next-generation RASP modulators (ADX-629, ADX-246, ADX-248), with multiple Phase 2 and planned Phase 1/2 trials across systemic and ocular diseases.
Financial Position: Aldeyra reported $174.3 million in cash, cash equivalents, and marketable securities at year-end 2022, projecting runway into the second half of 2024 with funding for potential product launches.
Reproxalap Differentiation: The 12-month safety study for Reproxalap showed a statistically significant 37% improvement in visual acuity over vehicle, a result not typically seen in dry eye studies.
Commercialization Readiness: Preparations are underway for U.S. launches of Reproxalap and ADX-2191, with robust partnering discussions ongoing for Reproxalap.
Key Catalysts Ahead: Several major clinical milestones are expected in 2023, including trial results for allergic conjunctivitis, chronic cough, and retinitis pigmentosa.
